|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
FY2020
12 months to Dec 31, 2020
|
|
|---|---|---|---|---|
| Cash Flows from Operating Activities: | ||||
| Net loss | ||||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Depreciation and amortization | ||||
| Stock-based compensation | ||||
| Foreign currency transaction loss | ||||
| Noncash interest expense | ||||
| Issuance of warrants | ||||
| Fair value adjustment of private placement warrant liability | ||||
| Fair value adjustment of earnout liability | ||||
| Gain (loss) on equity securities | ||||
| Inventory write-downs | ||||
| Loss on equity method investments | ||||
| Impairment of property and equipment | ||||
| Deferred income tax expense | ||||
| Deferred income tax (benefit) expense | ||||
| Accretion of discount on available-for-sale debt securities | ||||
| Restructuring and related charges | ||||
| Changes in operating assets and liabilities: | ||||
| Accounts receivable | ||||
| Inventory | ||||
| Prepaid expenses and other current assets | ||||
| Unbilled receivable | ||||
| Other assets | ||||
| Accounts payable | ||||
| Accrued liabilities | ||||
| Related party payables, net | ||||
| Contract liabilities | ||||
| Other liabilities | ||||
| Net cash used in operating activities | ||||
| Cash Flows from Investing Activities: | ||||
| Purchases of property and equipment | ||||
| Advanced payments for capital expenditures | ||||
| Investment in equity securities | ||||
| Proceeds from sales of property and equipment | ||||
| Investment in non-consolidated affiliates | ||||
| Purchases of short-term investments | ||||
| Proceeds from maturities of short-term investments | ||||
| Proceeds from sale of short-term investments | ||||
| Deconsolidation of subsidiary | ||||
| Net cash provided by (used in) investing activities | ||||
| Cash Flows from Financing Activities: | ||||
| Proceeds from sale of Units, net of underwriting discounts paid | ||||
| Payment of offering costs | ||||
| Proceeds from issuance of common stock, net of transaction costs | ||||
| Proceeds from Business Combination, net of redemption and transaction costs (Note 3) | ||||
| Payment under Horizon IP agreement | ||||
| Exercise of stock options | ||||
| Payment of finance lease liability | ||||
| Debt issuance costs | ||||
| Repurchase of warrants | ||||
| Net share settlement of equity awards | ||||
| Repurchase of common stock as treasury stock | ||||
| Deferred transaction costs | ||||
| Acquisition of noncontrolling interest | ||||
| Proceeds from issuance of convertible notes (Note 9) | ||||
| Net cash used in financing activities | ||||
| Cash at beginning of year | ||||
| Cash at end of year | ||||
| Effect of exchange rate changes on cash | ||||
| Net change in cash, cash equivalents, and restricted cash | ||||
| Cash, cash equivalents, and restricted cash — Beginning | ||||
| Cash, cash equivalents, and restricted cash — Ending | ||||
| Supplemental schedule of non-cash investing activities and financing activities: | ||||
| Conversion of Legacy Hyzon common stock | ||||
| Recognition of earnout liability in Business Combination | ||||
| Recognition of private placement warrant liability in Business Combination | ||||
| Horizon license agreement payable | ||||
| Conversion of convertible notes for common stock | ||||
| Acquisitions of property and equipment included in current liabilities | ||||
| Acquisition of noncontrolling interest included in operating assets | ||||
| Deconsolidation of subsidiary in exchange for related party receivable, net of cash held | ||||
Loading...